Cytovale vs Verse Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cytovale is developing a rapid point-of-care sepsis diagnostic — IntelliSep — that measures immune cell deformability via microfluidics to detect sepsis in ~8 minutes; received FDA Breakthrough Device Designation; raised $88M total;
About
Cytovale is a medical technology company headquartered in San Francisco, California, founded in 2014 by Lydia Sohn and others, with roots in biophysics research at the University of California, Berkeley. The company is developing the IntelliSep test — a rapid, near-patient diagnostic for sepsis that uses a proprietary microfluidic technology to measure the mechanical properties (deformability) of immune cells in whole blood. Sepsis — a life-threatening systemic immune response to infection — kills approximately 270,000 Americans annually and is the leading cause of hospital mortality, yet current diagnostic approaches (blood cultures, lactate, clinical scoring systems) are slow, non-specific, and frequently fail to identify sepsis before it progresses to organ failure and septic shock.
Verse Medical provides a healthcare logistics and coordination platform for managing in-home care delivery; automates scheduling, inventory management, and care workflows for providers transitioning patients to home-based treatment settings.
About
Verse Medical is a healthcare technology company building software infrastructure for home-based care delivery. As the healthcare industry shifts high-acuity and post-acute care from hospitals and infusion centers into the home, Verse addresses the operational complexity this transition creates for providers. Its platform integrates real-time scheduling, clinical workflow automation, inventory and supply chain management, and data coordination — enabling nurses, infusion pharmacies, and home care organizations to manage complex in-home treatment programs at scale.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.